AI Article Synopsis
- The study evaluates the role of hepatoma-derived growth factor (HDGF) in epithelial ovarian cancer (EOC) and finds that its overexpression is linked to cancer progression and poor patient outcomes.
- Higher levels of HDGF, found in about 52.76% of EOC cases, are significantly associated with lymphatic metastasis and lower overall survival rates, establishing it as an independent prognostic factor.
- The findings suggest that HDGF could serve as a potential target for new treatments in managing EOC.
Article Abstract
Aim: To evaluate the expression and clinical significance of hepatoma-derived growth factor (HDGF) in epithelial ovarian cancer (EOC).
Background: Recent studies have demonstrated that HDGF overexpression correlates to the progression and poor prognosis in several kinds of cancers. However, the clinical significance and prognostic value of HDGF in EOC have not been investigated.
Methods: Expression of HDGF was visualized by immunohistology and then the cohort was divided into higher- and lower-expression groups. The correlation between HDGF and clinicopathologic factors was analyzed by χ (2) test. The prognostic value of HDGF was assessed by univariate analysis with Kaplan-Meier method, and by multivariate analysis with Cox-regression model. With experiments in vitro, HDGF expression in ovarian cancer cell lines was detected by immunoblotting.
Results: Higher HDGF expression rate was 52.76% in EOC. HDGF expression was significantly associated with lymphatic metastasis (P=0.006). Higher HDGF expression was closely correlated to poorer 5-year overall survival rate with univariate analysis (P=0.003), and was identified as an independent prognostic factor with multivariate analysis (P=0.007). With experiments in vitro, HDGF was proved to exist in all ovarian cancer cell lines with different expression levels.
Conclusion: HDGF expression correlates to unfavorable prognosis and can be considered as an independent prognostic factor, indicating that HDGF may be a promising potential molecular drug target.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540117 | PMC |
| http://dx.doi.org/10.2147/OTT.S85660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of circulating plasma proteins in prostate cancer using mendelian randomization.
Discov Oncol
September 2024
Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, China.
Background: The proteome is an important resource for exploring potential diagnostic and therapeutic targets for cancer. This study aimed to investigate the causal associations between plasma proteins and prostate cancer (PCa), and to explore the downstream phenotypes that plasma proteins may influence and potential upstream intervening factors.
Methods: Proteome-wide Mendelian randomization was used to investigate the causal effects of plasma proteins on PCa.
FGFR‑related phenotypic and functional profile of CAFs in prognostication of breast cancer (Review).
Int J Oncol
October 2024
Department of Pathology, Chair of Oncology, Medical University of Lodz, 92‑213 Łodz, Poland.
Article Synopsis
- FGFR signaling is linked to breast cancer progression in preclinical studies, but clinical evidence is inconclusive.
- A review focused on cancer-associated fibroblasts (CAFs) and their role in influencing FGFR function, analyzing factors associated with CAFs that could impact breast cancer outcomes.
- Findings indicated that several CAF markers are associated with poor prognosis in breast cancer, highlighting the need for a deeper analysis of the stroma to better understand FGFR's clinical significance.
The m6A reader IGF2BP2 promotes ESCC progression by stabilizing HDGF mRNA.
J Cancer Res Ther
August 2024
Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324, Jing Wu Road, Jinan, China.
Objective: This study aimed to explore the role of IGF2BP2 in esophageal squamous cell carcinoma (ESCC) progression.
Materials And Methods: The Cancer Genome Atlas (TCGA) dataset, transcriptome sequencing, and the Gene Expression Omnibus (GEO) dataset were used to detect the expression of m6A-associated genes in ESCC. The in vitro and in vivo assays were used to explore the role of IGF2BP2 in ESCC.
Basis of gene-specific transcription regulation by the Integrator complex.
Mol Cell
July 2024
Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, 8093 Zurich, Switzerland. Electronic address:
The Integrator complex attenuates gene expression via the premature termination of RNA polymerase II (RNAP2) at promoter-proximal pausing sites. It is required for stimulus response, cell differentiation, and neurodevelopment, but how gene-specific and adaptive regulation by Integrator is achieved remains unclear. Here, we identify two sites on human Integrator subunits 13/14 that serve as binding hubs for sequence-specific transcription factors (TFs) and other transcription effector complexes.
View Article and Find Full Text PDFThe Analysis of ceRNA Networks and Tumor Microenvironment in Endometrial Cancer.
J Cancer
February 2024
Department of Gynecology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Endometrial carcinoma is a life-threatening and aggressive tumor that affects women worldwide. ceRNAs and carcinoma-infiltrating immunocytes can be associated with tumor formation and progression. Therefore, investigating the unique mechanisms underlying endometrial carcinoma is crucial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!